Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
22.02.2011 12:00:00

Amedisys Reports Fourth Quarter Revenue and Earnings and Issues 2011 Guidance

Amedisys, Inc. (NASDAQ: AMED), a leading home health and hospice company, today reported its financial results for the fourth quarter and year ended December 31, 2010 and issues guidance for 2011.

Three-Month Periods Ended December 31, 2010 and 2009

• Net service revenue of $394.3 million compared to $405.5 million in 2009, a decrease of $11.2 million or 2.8%. Same store agencies decreased $8.0 million and $11.5 million of the decrease related to agencies closed during the year offset by $8.3 million in revenue related to start-up and acquisition agencies.

• Net income attributable to Amedisys, Inc. of $22.1 million compared to $37.8 million in 2009, a decrease of $15.7 or 41.5%.

• Diluted earnings per share of $0.77 compared to $1.35 per diluted share in 2009, a decrease of 43.0%. The weighted average number of diluted shares outstanding increased to approximately 28.5 million compared to 28.1 million in 2009.

• Earnings before interest, taxes, depreciation and amortization ("EBITDA”) of $47.6 million compared to $71.3 million in 2009, a decrease of 33.2%.

• After adding back $8.5 million ($5.2 million, net of income tax) or $0.18 per diluted share in certain items*, the following would have been our adjusted results:

• Net income attributable to Amedisys, Inc. of $27.3 million compared to $37.8 million in 2009, a decrease of 27.9%.

• Diluted earnings per share of $0.95 compared to $1.35 per diluted share in 2009, a decrease 29.6%.

• EBITDA of $54.8 million compared to $71.3 million in 2009, a decrease of 23.2%.

Twelve-Month Periods Ended December 31, 2010 and 2009

• Net service revenue of $1.6 billion compared to $1.5 billion in 2009, an increase of $120.8 million or 8.0%. Same store agencies increased $71.4 million and $70.9 million of the increase is related to start-up and acquisition agencies offset by $21.5 million decrease in revenue from closed agencies.

• Net income attributable to Amedisys, Inc. of $112.6 million compared to $135.8 million in 2009, a decrease of $23.2 or 17.1%.

• Diluted earnings per share of $3.95 compared to $4.89 per diluted share in 2009, a decrease of 19.2%. The weighted average number of diluted shares outstanding increased to approximately 28.5 million compared to 27.8 million in 2009.

• EBITDA of $228.2 million compared to $261.8 million in 2009, a decrease of 12.8%.

• After adding back $15.9 million ($9.7 million, net of income tax) or $0.34 per diluted share in certain items*, the following would have been our adjusted results:

• Net income attributable to Amedisys, Inc. of $122.3 million compared to $135.8 million in 2009, a decrease of 10.0%.

• Diluted earnings per share of $4.29 compared to $4.89 per diluted share in 2009, a decrease 12.3%.

• EBITDA of $242.0 million compared to $261.8 million in 2009, a decrease of 7.6%.

* See footnote 2 on page 11 for explanation of these certain items.

William F. Borne, Chief Executive Officer of Amedisys, Inc. stated, "We responded to a number of operational issues in 2010. Many of the actions we initiated in the third quarter contributed to the improved earnings in the fourth quarter and will continue to have a positive impact in 2011. These actions have resulted in a stronger operational infrastructure to grow the business and continue to enhance the quality of care we provide our patients.”

2011 Guidance

• Net service revenue is anticipated to be in the range of $1.600 billion to $1.650 billion, excluding the effects of future acquisitions, if any are made.

• Diluted earnings per share is expected to be in the range of $3.00 to $3.30 based on an estimated 29.3 million shares outstanding. This guidance does not include the effects of any share repurchases, future acquisitions, any non-recurring costs that may be incurred during the year or the impact of any future Medicare rate changes.

We urge caution in considering the current trends and 2011 guidance disclosed in this press release. The home health and hospice industry is highly competitive and subject to intensive regulations, and trends and guidance are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission ("SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2010, and subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com. We disclaim any obligations to update disclosed information on trends.

Earnings Call and Webcast Information

To participate in the conference call, please dial (800) 967-7149 (Toll free) or (719) 325-2354 (Toll) a few minutes before 10:00 a.m. ET on Tuesday, February 22, 2011. A replay of the conference call will be available through March 1, 2011. The replay dial in number is (888) 203-1112 (Toll free) or (719) 457-0820 (Toll). The replay pin number is 9080078.

The call will also be available through our website and for seven days thereafter at the following web address: http://www.amedisys.com/investors.

We are headquartered in Baton Rouge, Louisiana. Our common stock trades on the NASDAQ Global Select Market under the symbol "AMED.”

Additional information

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled "Investors” on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like "believes,” "belief,” "expects,” "plans,” "anticipates,” "intends,” "projects,” "estimates,” "may,” "might,” "would,” "should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open agencies, acquire additional agencies and integrate and operate these agencies effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, changes in or developments with respect to any litigation or investigations relating to the Company, including the United States Senate Committee on Finance inquiry, the SEC investigation and the U.S. Department of Justice Civil Investigative Demand and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Non-GAAP Financial Measures

This press release includes the following non-GAAP financial measures as defined under SEC rules: EBITDA, defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, adjusted EBITDA, defined as EBITDA plus certain items, adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. plus certain items and adjusted diluted earnings per share, defined as diluted earnings per share plus the earnings per share effect of certain items. In accordance with SEC rules, we have provided herein a reconciliation of these non-GAAP financial measures to the most directly comparable measures under generally accepted accounting principles ("GAAP”). Management believes that these are useful gauges of our performance and are common measures used in our industry to assess relative financial performance among companies.

             

AMEDISYS, INC. AND SUBSIDIARIES

SELECT CONSOLIDATED FINANCIAL STATEMENT DATA AND SUPPLEMENTAL INFORMATION

(Amounts in thousands, except per share data and statistical information)

(Unaudited)

Balance Sheet Information

 
 
As of December 31,
2010 2009
ASSETS
Current assets:
Cash and cash equivalents $ 120,295 $ 34,485
Patient accounts receivable, net of allowance for doubtful accounts of $20,977 and $26,371 141,549 150,269
Prepaid expenses 9,947 10,279
Other current assets   22,139     23,003  
 
Total current assets 293,930 218,036
 
Property and equipment, net of accumulated depreciation of $78,074 and $59,780 138,554 91,919
Goodwill 791,412 786,923
Intangible assets, net of accumulated amortization of $17,135 and $11,826 53,393 57,608
Other assets, net   22,536     17,865  
 
Total assets $ 1,299,825   $ 1,172,351  
 
 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable $ 23,374 $ 16,535
Payroll and employee benefits 100,700 119,619
Accrued expenses 36,149 33,035
Obligations due Medicare 4,618 4,618
Current portion of long-term obligations 37,178 44,254
Current portion of deferred income taxes   14,285     11,245  
 
Total current liabilities 216,304 229,306
 
Long-term obligations, less current portion 144,688 170,899
Deferred income taxes 52,286 29,399
Other long-term obligations   6,832     6,412  
 
Total liabilities   420,110     436,016  
 
 
Commitments and Contingencies
 
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding
Common stock, $0.001 par value, 60,000,000 shares authorized; 29,867,701 and 28,303,216 shares issued; and 29,232,807 and 28,191,174 shares outstanding 29 28
Additional paid-in capital 407,156 363,670
Treasury stock at cost, 634,894 and 112,042 shares of common stock (14,022 ) (735 )
Accumulated other comprehensive income 25 114
Retained earnings   484,669     372,089  
 
Total Amedisys, Inc. stockholders’ equity 877,857 735,166
Noncontrolling interests   1,858     1,169  
 
Total equity   879,715     736,335  
 
Total liabilities and equity $ 1,299,825   $ 1,172,351  
                           

Income Statement Information

 
For the three-month periods ended December 31, For the Years Ended December 31,
2010 2009 2010 2009
Net service revenue $ 394,323 $ 405,472 $ 1,634,319 $ 1,513,459
Cost of service, excluding depreciation and amortization 200,784 197,370 820,460 724,465
General and administrative expenses:
Salaries and benefits 90,439 85,398 357,502 327,738
Non-cash compensation 2,317 2,108 10,634 7,848
Other 47,786 45,714 198,410 174,170
Provision for doubtful accounts 5,145 3,697 19,214 20,178
Depreciation and amortization   9,292     7,630     34,589     28,312  
 
Operating expenses   355,763     341,917     1,440,809     1,282,711  
 
Operating income 38,560 63,555 193,510 230,748
Other (expense) income:
Interest income 61 52 435 213
Interest expense (2,163 ) (2,575 ) (9,201 ) (11,670 )
Equity in earnings from unconsolidated joint ventures 706 622 3,016 2,343
Miscellaneous, net   (739 )   (219 )   (2,178 )   760  
 
Total other expense, net   (2,135 )   (2,120 )   (7,928 )   (8,354 )
 
Income before income taxes 36,425 61,435 185,582 222,394
Income tax expense   (14,156 )   (23,397 )   (72,309 )   (86,171 )
 
Net income 22,269 38,038 113,273 136,223
Net (income) loss attributable to noncontrolling interests   (171 )   (246 )   (693 )   (386 )
 
Net income attributable to Amedisys, Inc. $ 22,098   $ 37,792   $ 112,580   $ 135,837  
 
Net income per share attributable to Amedisys, Inc. common stockholders:
Basic $ 0.79   $ 1.37   $ 4.02   $ 4.99  
 
Diluted $ 0.77   $ 1.35   $ 3.95   $ 4.89  
 
Weighted average shares outstanding:
Basic   28,105     27,607     28,032     27,231  
 
Diluted   28,528     28,095     28,484     27,759  
                         

Cash Flow Information

 
For the three-month periods ended December 31, For the Year Ended December 31,
2010 2009 2010 2009
Net cash provided by operating activities $ 33,665 $ 28,737 $ 206,273 $ 247,659
Net cash (used in) investing activities (31,956 ) (32,484 ) (73,616 ) (97,255 )
Net cash used in financing activities   (9,451 )   (6,928 )   (46,847 )   (118,766 )
 
Net increase (decrease) in cash and cash equivalents (7,742 ) (10,675 ) 85,810 31,638
Cash and cash equivalents at beginning of period   128,037     45,160     34,485     2,847  
 
Cash and cash equivalents at end of period $ 120,295   $ 34,485   $ 120,295   $ 34,485  
                                           

Supplemental Information – Home Health

 
For the Three-Months Ended March 31,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Episodic-based revenue $ 343.1 $ 18.6 $ $ 361.7 $ 301.8 $ 2.8 $ 304.6
Non-episodic revenue   17.5     1.3         18.8   16.2   0.7     16.9
 
Net service revenue 360.6 19.9 380.5 318.0 3.5 321.5
Same store episodic-based revenue growth (3)   14 %
 
Cost of service   174.6     12.4         187.0   150.6   2.9     153.5
 
Gross Margin 186.0 7.5 193.5 167.4 0.6 168.0
Other operating expenses   83.1     10.5     0.1     93.7   76.6   4.0     80.6
 
Operating income $ 102.9   $ (3.0 ) $ (0.1 ) $ 99.8 $ 90.8 $ (3.4 ) $ 87.4
 
Key Statistical Data:
Admissions:
Episodic-based 61,340 3,938 65,278 55,682 430 56,112
Non-episodic   9,085     907         9,992   9,419   72     9,491
 
Total admissions   70,425     4,845         75,270   65,101   502     65,603
 
Same store episodic-based admission growth (3)   10 %
 
Recertifications:
Episodic-based 48,004 1,711 49,715 48,374 390 48,764
Non-episodic   4,740     156         4,896   5,744   25     5,769
 
Total recertifications   52,744     1,867         54,611   54,118   415     54,533
 
Same store episodic-based recertification growth (3)   (1 )%
 
Completed Episodes:
Episodic-based   100,261     4,835         105,096   95,259   1,040     96,299
 
Visits:
Episodic-based 1,998,384 92,869 2,091,253 1,806,274 16,291 1,822,565
Non-episodic   196,715     11,357         208,072   193,606   2,749     196,355
 
Total visits   2,195,099     104,226         2,299,325   1,999,880   19,040     2,018,920
 
Cost per Visit $ 79.53   $ 119.00   $   $ 81.32 $ 75.32 $ 146.60   $ 76.05
 
Episodic-based visits per completed episode (4)   18.7     16.9         18.6   17.7   17.2     17.7
 
 
For the Three-Months Ended June 30,
2010 2009
Same Store Startups/
Acquisitions

Exit Activity
(1)

Total Same Store Other (2) Total
Financial Information (in millions):
Episodic-based revenue $ 356.2 $ 13.1 $ $ 369.3 $ 335.0 $ 2.7 $ 337.7
Non-episodic revenue   17.7     1.0         18.7   16.9   0.1     17.0
 
Net service revenue 373.9 14.1 388.0 351.9 2.8 354.7
Same store episodic-based revenue growth (3)   6 %
 
Cost of service   181.0     9.7         190.7   163.9   2.4     166.3
 
Gross Margin 192.9 4.4 197.3 188.0 0.4 188.4
Other operating expenses   87.7     10.7     0.6     99.0   82.5   4.6     87.1
 
Operating income $ 105.2   $ (6.3 ) $ (0.6 ) $ 98.3 $ 105.5 $ (4.2 ) $ 101.3
 
Key Statistical Data:
Admissions:
Episodic-based 60,110 2,966 63,076 57,835 374 58,209
Non-episodic   9,382     706         10,088   8,884   59     8,943
 
Total admissions   69,492     3,672         73,164   66,719   433     67,152
 
Same store episodic-based admission growth (3)   4 %
 
Recertifications:
Episodic-based 46,375 1,195 47,570 51,211 296 51,507
Non-episodic   4,609     127         4,736   5,501   25     5,526
 
Total recertifications   50,984     1,322         52,306   56,712   321     57,033
 
Same store episodic-based recertification growth (3)  

(9

)%

 
Completed Episodes:
Episodic-based   105,676     3,744         109,420   101,430   779     102,209
 
Visits:
Episodic-based 2,037,881 69,572 2,107,453 1,956,014 11,787 1,967,801
Non-episodic   203,229     10,054         213,283   214,973   2,741     217,714
 
Total visits   2,241,110     79,626         2,320,736   2,170,987   14,528     2,185,515
 
Cost per Visit $ 80.75   $ 122.36   $   $ 82.18 $ 75.48 $ 168.46   $ 76.10
 
Episodic-based visits per completed episode (4)   19.4     17.3         19.4   18.6   16.9     18.6
                                           
For the Three-Months Ended September 30,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Episodic-based revenue $ 336.9 $ 12.3 $ $ 349.2 $ 339.5 $ 3.4 $ 342.9
Non-episodic revenue   18.1     1.2         19.3   16.2   0.3     16.5
 
Net service revenue 355.0 13.5 368.5 355.7 3.7 359.4
Same store episodic-based revenue growth (3)   (1 )%
 
Cost of service   177.2     9.0         186.2   166.0   2.7     168.7
 
Gross Margin 177.8 4.5 182.3 189.7 1.0 190.7
Other operating expenses   87.6     9.9     3.4     100.9   82.4   5.0     87.4
 
Operating income $ 90.2   $ (5.4 ) $ (3.4 ) $ 81.4 $ 107.3 $ (4.0 ) $ 103.3
 
Key Statistical Data:
Admissions:
Episodic-based 60,556 2,916 63,472 57,087 680 57,767
Non-episodic   9,621     791         10,412   8,508   129     8,637
 
Total admissions   70,177     3,707         73,884   65,595   809     66,404
 
Same store episodic-based admission growth (3)   6 %
 
Recertifications:
Episodic-based 44,804 1,127 45,931 52,348 486 52,834
Non-episodic   4,453     141         4,594   5,090   86     5,176
 
Total recertifications   49,257     1,268         50,525   57,438   572     58,010
 
Same store episodic-based recertification growth (3)   (14 )%
 
Completed Episodes:
Episodic-based   101,379     3,618         104,997   103,979   1,128     105,107
 
Visits:
Episodic-based 1,986,014 66,353 2,052,367 2,020,117 18,753 2,038,870
Non-episodic   197,200     11,041         208,241   191,326   6,394     197,720
 
Total visits   2,183,214     77,394         2,260,608   2,211,443   25,147     2,236,590
 
Cost per Visit $ 81.17   $ 116.62   $   $ 82.38 $ 75.08 $ 108.07   $ 75.45
 
Episodic-based visits per completed episode (4)   19.2     16.9         19.1   18.7   16.2     18.7
 
 
For the Three-Months Ended December 31,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Episodic-based revenue $ 331.9 $ 6.4 $ $ 338.3 $ 345.8 $ 10.0 $ 355.8
Non-episodic revenue   17.9     0.2         18.1   17.5   0.5     18.0
 
Net service revenue 349.8 6.6 356.4 363.3 10.5 373.8
Same store episodic-based revenue growth (3)   (4 )%
 
Cost of service   176.1     4.6         180.7   173.9   7.7     181.6
 
Gross Margin 173.7 2.0 175.7 189.4 2.8 192.2
Other operating expenses   85.9     5.4     4.0     95.3   81.3   8.2     89.5
 
Operating income $ 87.8   $ (3.4 ) $ (4.0 ) $ 80.4 $ 108.1 $ (5.4 ) $ 102.7
 
Key Statistical Data:
Admissions:
Episodic-based 60,500 1,437 61,937 57,887 1,807 59,694
Non-episodic   10,044     115         10,159   9,215   237     9,452
 
Total admissions   70,544     1,552         72,096   67,102   2,044     69,146
 
Same store episodic-based admission growth (3)   5 %
 
Recertifications:
Episodic-based 44,779 755 45,534 50,265 1,387 51,652
Non-episodic   4,393     46         4,439   5,112   73     5,185
 
Total recertifications   49,172     801         49,973   55,377   1,460     56,837
 
Same store episodic-based recertification growth (3)   (11 )%
 
Completed Episodes:
Episodic-based   103,443     2,032         105,475   105,148   3,212     108,360
 
Visits:
Episodic-based 1,952,738 37,290 1,990,028 1,997,040 55,212 2,052,252
Non-episodic   192,445     2,407         194,852   200,622   8,247     208,869
 
Total visits   2,145,183     39,697         2,184,880   2,197,662   63,459     2,261,121
 
Cost per Visit $ 82.09   $ 115.13   $   $ 82.69 $ 79.09 $ 120.88   $ 80.26
 
Episodic-based visits per completed episode (4)   19.2     18.4         19.2   19.0   17.6     19.0
                                           
For the Year Ended December 31,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Episodic-based revenue $ 1,368.1 $ 50.4 $ $ 1,418.5 $ 1,322.1 $ 18.9 $ 1,341.0
Non-episodic revenue   71.2     3.7         74.9   66.8   1.6     68.4
 
Net service revenue 1,439.3 54.1 1,493.4 1,388.9 20.5 1,409.4
Same store episodic-based revenue growth (3)   3 %
 
Cost of service   708.9     35.7         744.6   654.4   15.7     670.1
 
Gross Margin 730.4 18.4 748.8 734.5 4.8 739.3
Other operating expenses   344.3     36.5     8.1     388.9   322.8   21.8     344.6
 
Operating income $ 386.1   $ (18.1 ) $ (8.1 ) $ 359.9 $ 411.7 $ (17.0 ) $ 394.7
 
Key Statistical Data:
Admissions:
Episodic-based 242,506 11,257 253,763 228,491 3,291 231,782
Non-episodic   38,132     2,519         40,651   36,026   497     36,523
 
Total admissions   280,638     13,776         294,414   264,517   3,788     268,305
 
Same store episodic-based admission growth (3)   6 %
 
Recertifications:
Episodic-based 183,962 4,788 188,750 202,198 2,559 204,757
Non-episodic   18,195     470         18,665   21,447   209     21,656
 
Total recertifications   202,157     5,258         207,415   223,645   2,768     226,413
 
Same store episodic-based recertification growth (3)   (9 )%
 
Completed Episodes:
Episodic-based   410,759     14,229         424,988   405,816   6,159     411,975
 
Visits:
Episodic-based 7,975,017 266,084 8,241,101 7,779,445 102,043 7,881,488
Non-episodic   789,589     34,859         824,448   800,527   20,131     820,658
 
Total visits   8,764,606     300,943         9,065,549   8,579,972   122,174     8,702,146
 
Cost per Visit $ 80.88   $ 118.77   $   $ 82.13 $ 76.26 $ 127.91   $ 77.00
 
Episodic-based visits per completed episode (4)   19.2     17.2         19.1   18.5   17.2     18.5
 
(1) Exit activity includes the results for the periods subsequent to the agencies closures or consolidations.
(2) Agencies for the prior period which are not considered same store agencies during 2010 (i.e. agencies closed or consolidated in current period or unopened startups).
(3) Same store episodic-based revenue, admissions or recertifications growth is the percent increase in our same store episodic-based revenue, admissions or recertifications for the period as a percent of the same store episodic-based revenue, admissions or recertifications of the prior period.
(4) Episodic-based visits per completed episode as the home health episodic-based visits on completed episodes divided by the home health episodic-based episodes completed during the period.

Supplemental Information – Hospice

                                           
For the Three-Months Ended March 31,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Medicare revenue $ 25.4 $ 5.4 $ $ 30.8 $ 19.1 $ $ 19.1
Non-Medicare revenue   1.4     0.3       1.7   1.2       1.2
 
Net service revenue 26.8 5.7 32.5 20.3 20.3
Same store medicare revenue growth (3)   33 %
 
Cost of service   13.4     3.7       17.1   11.2   0.3     11.5
 
Gross margin 13.4 2.0 15.4 9.1 (0.3 ) 8.8
Other operating expenses   5.8     2.6       8.4   5.3   0.4     5.7
 
Operating income $ 7.6   $ (0.6 ) $ $ 7.0 $ 3.8 $ (0.7 ) $ 3.1
 
Key Statistical Data:
Hospice admits 2,237 556 2,793 1,983 1,983
Hospice days 195,966 40,553 236,519 153,914 153,914
Average daily census 2,177 451 2,628 1,710 1,710
Revenue per day $ 136.54 $ 141.08 $ $ 137.32 $ 132.00 $ $ 132.00
Cost of service per day $ 68.03 $ 92.68 $ $ 72.26 $ 73.02 $ $ 74.68
Average length of stay 89 79 87 74 74
                                           
For the Three-Months Ended June 30,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Medicare revenue $ 26.9 $ 5.4 $ $ 32.3 $ 22.0 $ $ 22.0
Non-Medicare revenue   1.7     0.3         2.0   1.2       1.2
 
Net service revenue 28.6 5.7 34.3 23.2 23.2
Same store medicare revenue growth (3)   22 %
 
Cost of service   14.8     3.8         18.6   11.8   0.3     12.1
 
Gross margin 13.8 1.9 15.7 11.4 (0.3 ) 11.1
Other operating expenses   5.9     2.7         8.6   5.5   0.5     6.0
 
Operating income $ 7.9   $ (0.8 ) $   $ 7.1 $ 5.9 $ (0.8 ) $ 5.1
 
Key Statistical Data:
Hospice admits 2,364 510 2,874 2,146 2,146
Hospice days 215,375 42,797 258,172 177,248 177,248
Average daily census 2,367 470 2,837 1,948 1,948
Revenue per day $ 132.87 $ 133.03 $ $ 132.90 $ 131.90 $ $ 131.90
Cost of service per day $ 68.63 $ 89.07 $ $ 72.02 $ 66.60 $ $ 68.34
Average length of stay 87 87 87 77 77
 
For the Three-Months Ended September 30,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Medicare revenue $ 30.7 $ 3.5 $ $ 34.2 $ 27.0 $ $ 27.0
Non-Medicare revenue   1.8     0.2         2.0   1.9       1.9
 
Net service revenue 32.5 3.7 36.2 28.9 28.9
Same store medicare revenue growth (3)   14 %
 
Cost of service   17.5     2.6         20.1   14.6   0.3     14.9
 
Gross margin 15.0 1.1 16.1 14.3 (0.3 ) 14.0
Other operating expenses   7.1     2.3     0.3     9.7   6.8   0.7     7.5
 
Operating income $ 7.9   $ (1.2 ) $ (0.3 ) $ 6.4 $ 7.5 $ (1.0 ) $ 6.5
 
Key Statistical Data:
Hospice admits 2,432 350 2,782 2,339 3 2,342
Hospice days 247,053 26,936 273,989 218,112 127 218,239
Average daily census 2,685 293 2,978 2,371 1 2,372
Revenue per day $ 131.73 $ 134.17 $ $ 131.97 $ 131.34 $ 120.17 $ 131.34
Cost of service per day $ 70.73 $ 96.61 $ $ 73.28 $ 66.77 $ $ 68.17
Average length of stay 91 61 87 84 49 83

 

 

 

 

 

 

 

Financial Information (in millions):
Medicare revenue $ 34.2 $ 1.7 $ $ 35.9 $ 29.2 $ 0.9 $ 30.1
Non-Medicare revenue   2.0             2.0   1.5   0.1     1.6
 
Net service revenue 36.2 1.7 37.9 30.7 1.0 31.7
Same store medicare revenue growth (3)   17 %
 
Cost of service   18.6     1.5         20.1   15.1   0.8     15.9
 
Gross margin 17.6 0.2 17.8 15.6 0.2 15.8
Other operating expenses   6.5     1.2     (0.1 )   7.6   7.5   0.9     8.4
 
Operating income $ 11.1   $ (1.0 ) $ 0.1   $ 10.2 $ 8.1 $ (0.7 ) $ 7.4
 
Key Statistical Data:
Hospice admits 2,905 156 3,061 2,431 100 2,531
Hospice days 269,872 12,657 282,529 228,457 6,719 235,176
Average daily census 2,933 138 3,071 2,483 73 2,556
Revenue per day $ 134.05 $ 140.90 $ $ 134.35 $ 135.02 $ 136.63 $ 135.07
Cost of service per day $ 69.18 $ 114.63 $ $ 71.21 $ 65.97 $ 120.62 $ 67.53
Average length of stay 90 49 88 91 58 90
                                           
For the Year Ended December 31,
2010 2009
Same Store Startups/
Acquisitions
Exit Activity
(1)
Total Same Store Other (2) Total
Financial Information (in millions):
Medicare revenue $ 117.2 $ 16.0 $ — $ 133.2 $ 97.3 $ 0.9 $ 98.2
Non-Medicare revenue 6.9 0.8 7.7 5.8 0.1 5.9
 
Net service revenue 124.1 16.8 140.9 103.1 1.0 104.1
Same store medicare revenue growth (3) 20 %
 
Cost of service 64.3 11.6 75.9 52.7 1.7 54.4
 
Gross margin 59.8 5.2 65.0 50.4 (0.7 ) 49.7
Other operating expenses 25.3 8.8 0.2 34.3 25.1 2.5 27.6
 
Operating income $ 34.5 $ (3.6 ) $ (0.2 ) $ 30.7 $ 25.3 $ (3.2 ) $ 22.1
 
Key Statistical Data:
Hospice admits 9,938 1,572 11,510 8,899 103 9,002
Hospice days 928,266 122,943 1,051,209 777,731 6,846 784,577
Average daily census 2,543 337 2,880 2,131 19 2,150
Revenue per day $ 133.68 $ 136.75 $ — $ 134.04 $ 132.68 $ 136.32 $ 132.71
Cost of service per day $ 69.22 $ 94.54 $ — $ 72.18 $ 67.73 $ 246.54 $ 69.29
Average length of stay 89 75 87 82 61 82
(1)   Exit activity includes the results for the periods subsequent to the agencies closure or consolidation.
(2) Agencies for the prior period which are not considered same store agencies during 2010 (i.e. agencies closed or consolidated in current period or unopened startups).
(3) Same Store Medicare revenue growth is the percent increase in our same store Medicare revenue for the period as a percent of the same store Medicare revenue of the prior period.
                         

AMEDISYS, INC. AND SUBSIDIARIES

SELECT CONSOLIDATED KEY STATISTICAL AND FINANCIAL DATA

(Financial Data in thousands)

(Unaudited)

 
For the three-month periods ended December 31, For the Year Ended December 31,
2010 2009 2010 2009
Financial Data:
Depreciation and amortization expense $ 9,292 $ 7,630 $ 34,589 $ 28,312
Capital expenditures $ 26,436 $ 10,361 $ 63,971 $ 36,359
Key Statistical Data:
General
Number of home health agencies (1) 486 521 486 521
Number of hospice agencies (1) 67 65 67 65
Number of agencies acquired (2) 1 1 4 20
Number of agencies opened as start-up locations (2) 6 17 48 48
Days revenue outstanding, net (3) 32.8 33.9 32.8 33.9
Same store episodic-based revenue growth (4) (4 )% 13 % 3 % 16 %
Internal episodic-based revenue growth (5) (5 )% 15 % 4 % 18 %
Same store episodic-based admission growth(4) 5 % 5 % 6 % 3 %
Internal episodic-based admission growth (5) 4 % 7 % 8 % 6 %
Same store episodic-based recertification growth (4) (11 )% 1 % (9 )% 7 %
Internal episodic-based recertification growth (5) (12 )% 2 % (9 )% 8 %
Home Health
Average episodic-based revenue per completed episode (6) $ 3,294 $ 3,260 $ 3,311 $ 3,166
(1)   Includes the closure/consolidation of 57 and 78 home health agencies and 6 and 7 hospice agencies during the three and twelve-month periods ended December 31, 2010, respectively.
(2) Includes both home health and hospice agencies.
(3) Our calculation of days revenue outstanding, net at December 31, 2010 and 2009 is derived by dividing our ending net patient accounts receivable (i.e. net of estimated revenue adjustments and allowance for doubtful accounts) by our average daily net patient revenue for the three-month period ended December 31, 2010 and 2009, respectively.
(4) Same store episodic-based revenue, admissions or recertifications growth is the percent increase in our same store episodic-based revenue, admissions or recertifications for the period as a percent of the same store episodic-based revenue, admissions or recertifications of the prior period.
(5) Internal episodic-based revenue, admission or recertification growth is the percent increase in our base/start-up episodic-based revenue, admissions or recertifications for the period as a percent of the total episodic-based revenue, admissions or recertifications of the prior period.
(6) Average episodic-based revenue per completed episode is the average episodic-based revenue earned for each episodic-based completed episode of care.
                         

AMEDISYS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURE TO GAAP FINANCIAL STATEMENTS

(Amounts in thousands, except per share data)

(Unaudited)

Earnings before interest, taxes, depreciation and amortization ("EBITDA”) and Adjusted EBITDA

 
For the three-month periods ended
December 31,
For the Year Ended
December 31,
2010 2009 2010 2009
Net income attributable to Amedisys, Inc. $ 22,098 $ 37,792 $ 112,580 $ 135,837
Add:
Provision for income taxes 14,156 23,397 72,309 86,171
Interest expense, net 2,102 2,523 8,766 11,457
Depreciation and amortization   9,292     7,630   34,589     28,312
 
EBITDA (1) $ 47,648   $ 71,342 $ 228,244   $ 261,777
 
 
Add:
Certain items (2)

 

8,467

15,947
Intangible write-off (2)   (1,343 )     (2,216 )  
 
Adjusted EBITDA (3) $

54,772

  $ 71,342 $ 241,975   $ 261,777
 

Adjusted Net Income Attributable to Amedisys, Inc. Reconciliation

For the three-month periods ended
December 31,
For the Year Ended
December 31,
2010 2009 2010 2009
Net income attributable to Amedisys, Inc. $ 22,098 $ 37,792 $ 112,580 $ 135,837
Add:
Certain items (2)   5,165       9,728    
 
Adjusted net income attributable to Amedisys, Inc. (4) $ 27,263   $ 37,792 $ 122,308   $ 135,837
 

Adjusted Diluted Earnings Per Share Reconciliation

For the three-month periods ended
December 31,
For the Year Ended
December 31,
2010 2009 2010 2009
Net income attributable to Amedisys, Inc. common stockholders - diluted $ 0.77 $ 1.35 $ 3.95 $ 4.89
Add:
Certain items (2)   0.18       0.34    
 
Adjusted net income attributable to Amedisys, Inc. common stockholders - diluted (5) $ 0.95   $ 1.35 $ 4.29   $ 4.89
(1)   EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense, and depreciation and amortization. EBITDA should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of EBITDA may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.
(2) During the three-month period December 31, 2010 we incurred certain costs associated with the realignment of operations including severance and legal expenses related to the United States Senate Committee on Finance inquiry and SEC investigation. We also incurred costs associated with our exit activities for the three-and twelve month periods ended December 31, 2010, which includes $1.3 million and $2.2 million respectively, for the write-off of intangibles. During the three-month period ended September 30, 2010 we settled our Georgia indigent care liability for less than previously accrued and during the three-month period June 30, 2010 we received the Centers for Medicare and Medicaid Services ("CMS”) bonus payments as the result of a pay for performance demonstration. The following details these items for the three and twelve-month periods ended December 31, 2010:
                                     
For the three-month period ended
December 31, 2010
For the Year Ended
December 31, 2010
Income
(Expense)
Net of tax Diluted EPS Income
(Expense)
Net of tax Diluted EPS
Georgia indigent care liability $ $ $ $ 3,676 $ 2,242 $ 0.08
CMS bonus payment 3,587 2,188 0.08
Exit activities (5,261 ) (3,210 ) (0.11 ) (13,601 ) (8,297 ) (0.29 )
Certain costs   (3,206 )   (1,955 )   (0.07 )   (9,609 )   (5,861 )   (0.21 )
 
Total $ (8,467 ) $ (5,165 ) $ (0.18 ) $ (15,947 ) $ (9,728 ) $ (0.34 )
(3)   Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense, depreciation and amortization plus certain items as described in footnote 2. Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of adjusted EBITDA may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.
(4) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. plus certain items as described in footnote 2. Adjusted net income attributable to Amedisys, Inc. should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of adjusted net income attributable to Amedisys, Inc. may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP measure in the same manner.
(5) Adjusted diluted earnings per share is defined as diluted earnings per share plus the earnings per share effect of certain items as described in footnote 2. Adjusted diluted earnings per share should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators or operating performance. This calculation of adjusted diluted earnings per share may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Office Depot Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Office Depot Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

S&P 500 5 969,34 0,35%